The goals of this activity are to improve the prevention and diagnosis of cardiovascular disease, as well as the management of patients with cardiovascular disease. After completing the activity, the clinician will be better able to: 1.Summarize efficacy and safety data on the short- and long-term use of the novel lipid-lowering agents alirocumab and evolocumab. 2.List pros and cons related to 6 months versus >12 months of dual antiplatelet therapy following stenting. 3.Describe the role, if any, for clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. 4.Discuss the level of attainment of optimal medical therapy goals in patients with coronary artery disease enrolled in clinical trials and consider the take-away lessons for clinical practice.
Ratings and Reviews
To review this course, please login.Login